Compare AGCO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGCO | EXEL |
|---|---|---|
| Founded | 1990 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 11.4B |
| IPO Year | 1994 | 2000 |
| Metric | AGCO | EXEL |
|---|---|---|
| Price | $121.23 | $44.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $118.73 | $46.45 |
| AVG Volume (30 Days) | 584.3K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 271.35 | 57.95 |
| EPS | ★ 9.75 | 2.78 |
| Revenue | ★ $10,082,000,000.00 | $452,477,000.00 |
| Revenue This Year | $6.55 | $13.66 |
| Revenue Next Year | $5.59 | $13.39 |
| P/E Ratio | ★ $12.54 | $16.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $78.37 | $33.76 |
| 52 Week High | $143.78 | $48.74 |
| Indicator | AGCO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 58.52 |
| Support Level | $102.57 | $40.53 |
| Resistance Level | $143.78 | $45.88 |
| Average True Range (ATR) | 3.31 | 1.04 |
| MACD | 1.17 | 0.33 |
| Stochastic Oscillator | 79.87 | 73.68 |
Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealer and distribution locations and reach into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its unconsolidated joint venture with Rabobank of the Netherlands.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.